Corbus Pharmaceuticals Holdings, Inc. (CRBP) Social Stream
Featured Post From StockTwits About CRBP
$CRBP Did anyone else get an email to vote on the annual meeting of stockholders? This item that the board is voting for has me concerned.TooMuchTime, published April 21, 2021
"To approve an amendment to the Company's certificate of incorporation, as amended, to increase the Company's authorized shares of common stock from 150,000,000 to 300,000,000."
What Else are CRBP Traders Talking About?
Other tickers frequently mentioned alongside CRBP is JPM.
Other Notable StockTweets About CRBP
$CRBP for those wondering they have $85 mil in cash and $26 mil in debt. They have enough funding from the offering last year at $6.60 to last them well into 2023. There is no real risk of dilution.
Btw not to mention huge institutional buyers: (they own roughly 76% of shares)
Bio's taking a hit, but will come back in time, no rush
-> 3.00 (+0%): Data being presented at AACR tomorrow, should get PR Monday
-> 1.77 (+3%)
-> 3.18 (-11%)
-> 3.54 (+92%) Long term hold
CALA -> 3.03 (-15%)- Holding for catalysts in H2 of 2021, will add to my position once closer to these
-> 4.15 (+7%)- Presenting Pre-clinical data at AACR this weekend
ASMB -> 4.60 (-5%)
-> 4.10 (+1%)
$RESN: Have been accumulating here is 4.01 (-2.5%)
$CRBP: Holding some $2 May Calls at 0.27 (+2%)
New Position: Took some $JPM 5/21 $165 Calls today, was purchasing throughout the day and average is 2.07 (+5%). Earnings next week
Up to 30 realized wins and no realized losses for 2021
Chairty Account is up 13% from initial seed of $1k and is holding VBIV and GLYC
Happy Trading and Have a great weekend!
$CRBP For people who keep spamming this feed and say the stock will fall @CharlieEscobar . I would like to let you know that hedge fund managers who own the overwhelming majority of this stock are not reading this feed, so your efforts to get people to sell so that you can a couple of dollars shorting alas will not bear fruit.aromman, published April 6, 2021
This study is the largest randomized, double-blind, placebo-controlled dermatomyositis study to date. Subjects were randomized 2:1:2 to either receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day, or placebo twice per day.
The primary efficacy endpoint is the composite American College of Rheumatology/European League Against Rheumatism 2016 Total Improvement Score ("Total Improvement Score") at Week 28. Change from baseline will be provided for each component of the Total Improvement Score to support this composite endpoint. Definition of Improvement, Investigator Global Assessment scale of skin activity, and Cutaneous Dermatomyositis Activity and Severity Index activity score are among secondary efficacy endpoints.
Lenabasum was granted Orphan Drug Designation for the treatment of dermatomyositis from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).